Hepatitis B vaccination in chronic kidney disease patients: A call for novel vaccines

Expert Review of Vaccines

Volumn 13, Issue 11, 2014, Pages 1317-1326

  Grzegorzewska, Alicja E ^a  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

Author keywords

adjuvants; chronic kidney disease; dialysis; hepatitis B vaccination; immunization rate; immunocompromised state; renal transplantation; third generation vaccines

Indexed keywords

CPG OLIGODEOXYNUCLEOTIDE; HEMOKININ 1; HEPATITIS B VACCINE; IMMUNOSTIMULATING AGENT; OLIGODEOXYRIBONUCLEOTIDE; PHOSPHOROTHIOIC ACID; POLYSACCHARIDE; RECOMBINANT HEPATITIS B VACCINE; UNCLASSIFIED DRUG;

CHRONIC KIDNEY DISEASE; COMMERCIAL PHENOMENA; DRUG TREATMENT FAILURE; GRAFT RECIPIENT; HUMAN; IMMUNOGENICITY; KIDNEY GRAFT; NONHUMAN; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; VACCINATION; HEPATITIS B; IMMUNOLOGY; PROCEDURES; RENAL INSUFFICIENCY, CHRONIC; RENAL REPLACEMENT THERAPY;

HEPATITIS B; HEPATITIS B VACCINES; HUMANS; RENAL DIALYSIS; RENAL INSUFFICIENCY, CHRONIC; VACCINATION;

EID: 84911461337     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/14760584.2014.944508     Document Type: Review

References (105)

1. Shakhgil'dian IV, Khukhlovich PA, Savin EA, et al. [Risk of infection with hepatitis B and C viruses of medical workers, patients in the hemodialysis ward, and vaccine prophylaxis of hepatitis B infection in these populations]. Article in Russian Vopr Virusol 1994;39:226-9
2. Vermeiren AP, Hoebe CJ, Dukers-Muijrers NH. High non-responsiveness of males and the elderly to standard hepatitis B vaccination among a large cohort of healthy employees. J Clin Virol 2013;58:262-4
3. Watanabe H, Matsushita S, Kamikawaji N, et al. Immune suppression gene on HLABw54-DR4-DRw53 haplotype controls nonresponsiveness in humans to hepatitis B surface antigen via CD8+ suppressor T cells. Hum Immunol 1988;22:9-17
4. Pol S, Legendre C, Mattlinger B, et al. Genetic basis of nonresponse to hepatitis B vaccine in hemodialyzed patients. J Hepatol 1990;11:385-7
5. Milich DR, Leroux-Roels GG. Immunogenetics of the response to HBsAg vaccination. Autoimmun Rev 2003;2: 248-57
6. Thursz M. MHC and the viral hepatitides. QJM 2001;94:287-91
7. Girndt M, Sester U, Sester M, et al. The interleukin-10 promoter genotype determines clinical immune function in hemodialysis patients. Kidney Int 2001;60: 2385-91
8. Grzegorzewska AE, Wobszal P, Jagodziński PP. Interleukin-18 promoter polymorphism and development of antibodies to surface antigen of hepatitis B virus in hemodialysis patients. Kidney Blood Press Res 2012;35:1-8
9. Grzegorzewska AE, Wobszal PM, Mostowska A, et al. Antibodies to hepatitis B virus surface antigen and interleukin 12 and interleukin 18 gene polymorphisms in hemodialysis patients. BMC Nephrol 2012;13:75
10. Grzegorzewska AE, Pajzderski D, Sowińska A, et al. IL4R and IL13 polymorphic variants and development of antibodies to surface antigen of hepatitis B virus in hemodialysis patients in response to HBV vaccination or infection. Vaccine 2013;31:1766-70
11. Grzegorzewska AE, Wobszal PM, Sowińska A, et al. Association of the interleukin-12 polymorphic variants with the development of antibodies to surface antigen of hepatitis B virus in hemodialysis patients in response to vaccination or infection. Mol Biol Rep 2013;40:6899-911
12. Grzegorzewska AE, Pajzderski D, Sowińska A, et al. Polymorphism of monocyte chemoattractant protein 1 (MCP1-2518 A/G) and responsiveness to hepatitis B vaccination in hemodialysis patients. Pol Arch Med Wewn 2014;124: 10-18
13. Fraser GM, Ochana N, Fenyves D, et al. Increasing serum creatinine and age reduce the response to hepatitis B vaccine in renal failure patients. J Hepatol 1994;21:450-4
14. Shatat HZ, Kotkat AM, Farghaly AG. Immune response to hepatitis B vaccine in haemodialysis patients. J Egypt Public Health Assoc 2000;75:257-75
15. Jadoul M, Goubau P. Is anti-hepatitis B virus (HBV) immunization successful in elderly hemodialysis (HD) patients? Clin Nephrol 2002;58:301-4
16. Fabrizi F, Martin P, Dixit V, et al. Metaanalysis: the effect of age on immunological response to hepatitis B vaccine in end-stage renal disease. Aliment Pharmacol Ther 2004;20:1053-62
17. Lin SY, Liu JH, Wang SM, et al. Association of response to hepatitis B vaccination and survival in dialysis patients. BMC Nephrol 2012;13:97
18. Stevens CE, Alter HJ, Taylor PE, et al. Hepatitis B vaccine in patients receiving hemodialysis. Immunogenicity and efficacy. N Engl J Med 1984;311:496-501
19. Elkayam O, Yaron M, Caspi D. Safety and efficacy of vaccination against hepatitis B in patients with rheumatoid arthritis. Ann Rheum Dis 2002;61:623-5
20. Fernández E, Betriu MA, Gómez R, et al. Response to the hepatitis B virus vaccine in haemodialysis patients: influence of malnutrition and its importance as a risk factor for morbidity and mortality. Nephrol Dial Transplant 1996;11:1559-63
21. Chow KM, Law MC, Leung CB, et al. Antibody response to hepatitis B vaccine in end-stage renal disease patients. Nephron Clin Pract 2006;103:c89-93
22. Verkade MA, Van Druningen CJ, Vaessen LM, et al. Functional impairment of monocyte-derived dendritic cells in patients with severe chronic kidney disease. Nephrol Dial Transplant 2007;22:128-38
23. Hesselink DA, Betjes MG, Verkade MA, et al. The effects of chronic kidney disease and renal replacement therapy on circulating dendritic cells. Nephrol Dial Transplant 2005;20:1868-73
24. Kurz P, Köhler H, Meuer S, et al. Impaired cellular immune responses in chronic renal failure: evidence for a T cell defect. Kidney Int 1986;29:1209-14
25. Chatenoud L, Dugas B, Beaurain G, et al. Presence of preactivated T cells in hemodialysis patients: their possible role in altered immunity. Proc Natl Acad Sci USA 1988;83:7457-61
26. Descamps-Latscha B, Herbelin A. Long-term dialysis and cellular immunity: a critical survey. Kidney Int 1993; 43(Suppl 4):S135-42
27. Litjens NH, van Druningen CJ, Betjes MG. Progressive loss of renal function is associated with activation and depletion of naive T lymphocytes. Clin Immunol 2006;118:83-91
28. Contin C, Pitard V, Delmas Y, et al. Potential role of soluble CD40 in the humoral immune response impairment of uraemic patients. Immunology 2003;110: 131-40
29. Mathew R, Mason D, Kennedy JS. Vaccination issues in patients with chronic kidney disease. Expert Rev Vaccines 2014;13:285-98
30. Zitt E, Sprenger-Mähr H, Knoll F, et al. Vitamin D deficiency is associated with poor response to active hepatitis B immunisation in patients with chronic kidney disease. Vaccine 2012;30:931-5
31. Duranti E, Duranti D. Polymethylmethacrylate strengthens antibody response in hemodialysis patients not responding to hepatitis B vaccine: preliminary data. Minerva Med 2011;102: 469-74
32. Schiffl H, Wendinger H, Lang SM. Ultrapure dialysis fluid and response to hepatitis B vaccine. Nephron 2002;91:530-1
33. Group KDIGOKCW. KDIGO. 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl 2013;3: 1-150
34. Agarwal SK, Irshad M, Dash SC. Comparison of two schedules of hepatitis B vaccination in patients with mild, moderate and severe renal failure. J Assoc Physicians India 1999;47:183-5
35. Seaworth B, Drucker J, Starling J, et al. Hepatitis B vaccines in patients with chronic renal failure before dialysis. J Infect Dis 1988;157:332-7
36. DaRoza G, Loewen A, Djurdjev O, et al. Stage of chronic kidney disease predicts seroconversion after hepatitis B immunization: earlier is better. Am J Kidney Dis 2003;42:1184-92
37. Hashemi B, Mahdavi-Mazdeh M, Abbasi M, et al. Efficacy of HBV vaccination in various stages of chronic kidney disease: is earlier better? Hepat Mon 2011;11:816-20
38. Ghadiani MH, Besharati S, Mousavinasab N, et al. Response rates to HB vaccine in CKD stages 3-4 and hemodialysis patients. J Res Med Sci 2012;17:527-33
39. McNulty CA, Bowen JK, Williams AJ. Hepatitis B vaccination in predialysis chronic renal failure patients a comparison of two vaccination schedules. Vaccine 2005;23:4142-7
40. Ahmadi F, Ramezani M, Razeghi E, et al. A randomized controlled trial of two schedules of hepatitis B vaccination in predialysed chronic renal failure patients. Hepat Mon 2012;12:344-8
41. Schillie SF, Spradling PR, Murphy TV. Immune response of hepatitis B vaccine among persons with diabetes: a systematic review of the literature. Diabetes Care 2012;35:2690-7
42. Lefebure AF, Verpooten GA, Couttenye MM, et al. Immunogenicity of a recombinant DNA hepatitis B vaccine in renal transplant patients. Vaccine 1993;11: 397-9
43. Bel'eed K, Wright M, Eadington D, et al. Vaccination against hepatitis B infection in patients with end stage renal disease. Postgrad Med J 2002;78:538-40
44. Grzegorzewska A.E. Hepatitis B vaccination in chronic kidney disease: review of evidence in non-dialyzed patients. Hepat Mon 2012;12:e7359
45. Joint Committee on Vaccination, Immunization, Great Britain. Dept. of Health. Immunisation against infectious disease. H.M. Stationery Office; London, UK: 1988
46. Great Britain. Dept. of Health. Immunisation against infectious disease. H. M. Stationery Office; London, UK: 1990
47. European Best Practice Guidelines Expert Group on Hemodialysis, European Renal Association. Section VI. Haemodialysis-associated infection. Nephrol Dial Transplant 2002;17(Suppl 7):72-87
48. Mast EE, Weinbaum CM, Fiore AE, et al. Advisory Committee on Immunization Practices (ACIP) Centers for Disease Control and Prevention (CDC). A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) Part II: immunization of adults. MMWR Recomm Rep 2006;55(RR-16): 1-33
49. Centers for Disease Control and Prevention (CDC). Use of hepatitis B vaccination for adults with diabetes mellitus: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2011;60:1709-11
50. Stel VS, van de Luijtgaarden MW, Wanner C, et al. The 2008 ERAEDTA Registry Annual Report-a precis. NDT Plus 2011;4:1-13
51. Tsouchnikas I, Dounousi E, Xanthopoulou K, et al. Loss of hepatitis B immunity in hemodialysis patients acquired either naturally or after vaccination. Clin Nephrol 2007;68:228-34
52. Roznovský L, Tvrdk J, Kabieszová L, et al. [Vaccination against hepatitis B in patients with chronic renal failure-twenty years follow-up]. Article in Czech Vnitr Lek 2011;57:808-14
53. Fabrizi F, Martin P. Hepatitis B virus infection in dialysis patients. Am J Nephrol 2000;20:1-11
54. Ribot S. Duration of hepatitis B surface antigenemia (HBsAg) in hemodialysis patients. Arch Intern Med 1979;139:178-80
55. Harnett JD, Parfrey PS, Kennedy M, et al. The long-term outcome of hepatitis B infection in hemodialysis patients. Am J Kidney Dis 1988;11:210-13
56. Rutkowski B, Lichodziejewska-Nienierko M, Grenda R, et al. Report on Renal Replacement Therapy in Poland-2010. Drukonsul, Gdańsk, Poland, 2013
57. S wiatowy Dzień Wirusowego Zapalenia Wa?troby-28 lipca 2013. Available from: http://wsse.krakow.pl/strona2/index.php/obszary-dzialan/nadzor-sanitarny/89-epidemiologia/87-swiatowy-dzienwirusowego-zapalenia-watroby-28-lipca-2013 [Last accessed 25 March 2014]
58. Grzegorzewska AE, Kaczmarek-Leki V, Młot-Michalska M, et al. Seroconversion rate to positivity for antibodies against core antigen of hepatitis B virus and duration of renal replacement therapy. Nephrol Dial Transplant 2011;26:970-6
59. Cendoroglo Neto M, Draibe SA, Silva AE, et al. Incidence of and risk factors for hepatitis B virus and hepatitis C virus infection among haemodialysis and CAPD patients: evidence for environmental transmission. Nephrol Dial Transplant 1995;10:240-6
60. Lewis-Ximenez LL, Oliveira JM, Mercadante LA, et al. Serological and vaccination profile of hemodialysis patients during an outbreak of hepatitis B virus infection. Nephron 2001;87:19-26
61. Lee YH, Hsu CY, Hsia CY, et al. Hepatocellular carcinoma in uremic patients: is there evidence for an increased risk of mortality? J Gastroenterol Hepatol 2013;28:348-56
62. Hwang JC, Weng SF, Weng RH. High incidence of hepatocellular carcinoma in ESRD patients: caused by high hepatitis rate or 'uremia'? a population-based study. Jpn J Clin Oncol 2012;42:780-6
63. Gulin M, Slavicek J, Basić-Jukić N, et al. [Outcome of renal transplantation in patients with chronic virus hepatitis]. Article in Croatian Acta Med Croatica 2011;65: 315-21
64. Uyar M, Sahin S, Dheir H, et al. The influence of hepatitis B and C virus infections on patient and allograft outcomes in kidney transplantation. Transplant Proc 2011;43:850-2
65. Tsai MC, Chen YT, Chien YS, et al. Hepatitis B virus infection and renal transplantation. World J Gastroenterol 2010;16:3878-87
66. Kalia H, Fabrizi F, Martin P. Hepatitis B virus and renal transplantation. Transplant Rev (Orlando) 2011;25:102-9
67. Milich DR, McLachlan A, Chisari FV, et al. Immune response to the pre-S(1) region of the hepatitis B surface antigen (HBsAg): a pre-S(1)-specific T cell response can bypass nonresponsiveness to the pre-S (2) and S regions of HBsAg. J Immunol 1986;137:315-22
68. Gerlich WH, Deepen R, Heermann KH, et al. Protective potential of hepatitis B virus antigens other than the S gene protein. Vaccine 1990;8(Suppl):S63-8
69. Jungers P, Chauveau P, Couroucé AM, et al. Recombinant vaccine and extracting vaccine against hepatitis B in patients with kidney insufficiency: comparative immunogenicity. Article in French Presse Med 1994;23:277-80
70. Jungers P, Chauveau P, Couroucé AM, et al. Immunogenicity of the recombinant GenHevac B Pasteur vaccine against hepatitis B in chronic uremic patients. J Infect Dis 1994;169:399-402
71. Weinstein T, Chagnac A, Boaz M, et al. Improved immunogenicity of a novel third-generation recombinant hepatitis B vaccine in patients with end-stage renal disease. Nephron Clin Pract 2004;97:c67-72
72. Levie K, Gjorup I, Skinhøj P, et al. A 2-dose regimen of a recombinant hepatitis B vaccine with the immune stimulant AS04 compared with the standard 3-dose regimen of Engerix-B in healthy young adults. Scand J Infect Dis 2002;34:610-14
73. Kuan RK, Janssen R, Heyward W, et al. Cost-effectiveness of hepatitis B vaccination using HEPLISAVTM in selected adult populations compared to Engerix-B-vaccine. Vaccine 2013;31:4024-32
74. Garçon N, Chomez P, Van Mechelen M. GlaxoSmithKline Adjuvant Systems in vaccines: concepts, achievements and perspectives. Expert Rev Vaccines 2007;6: 723-39
75. Tagliabue A, Rappuoli R. Vaccine adjuvants: the dream becomes real. Hum Vaccin 2008;4:347-9
76. Ulrich JT, Myers KR. Monophosphoryl lipid A as an adjuvant. Past experiences and new directions. Pharm Biotechnol 1995;6: 495-524
77. Garçon N. Preclinical development of AS04. Methods Mol Biol 2010;626:15-27
78. European Medicines Agency (EMA). European Public Assessment Reports (EPARs) for authorized medicinal products for human use. Fendrix. EPAR H-C-50. Available from: www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000550/human-med-000788. jsp&murl=menus/medicines/medicines. jsp&mid=WC0b01ac058001d124 [Last accessed 10 January 2014]
79. Boland G, Beran J, Lievens M, et al. Safety and immunogenicity profile of an experimental hepatitis B vaccine adjuvanted with AS04. Vaccine 2004;23:316-20
80. Jacques P, Moens G, Desombere I, et al. The immunogenicity and reactogenicity profile of a candidate hepatitis B vaccine in an adult vaccine non-responder population. Vaccine 2002;20:3644-9
81. Hoebe CJ, Vermeiren AP, Dukers-Muijrers NH. Revaccination with Fendrix-or HBVaxPro-results in better response rates than does revaccination with three doses of Engerix-B-in previous non-responders. Vaccine 2012;30:6734-7
82. Kong NC, Beran J, Kee SA, et al. Immunogenicity and safety of an adjuvanted hepatitis B vaccine in pre-hemodialysis and hemodialysis patients. Kidney Int 2005;68: 2298-303
83. Kong NC, Beran J, Kee SA, et al. A new adjuvant improves the immune response to hepatitis B vaccine in hemodialysis patients. Kidney Int 2008;73:856-62
84. Polito P, Di Lullo L, Iannacci GR, et al. Seroconversion and immune response after anti-HBV vaccination in patients on chronic hemodialysis: comparison of two vaccines. Article in Italian G Ital Nefrol 2011;28: 525-30
85. Verstraeten T, Descamps D, David MP, et al. Analysis of adverse events of potential autoimmune aetiology in a large integrated safety database of AS04 adjuvanted vaccines. Vaccine 2008;26:6630-8
86. Beran J. Safety and immunogenicity of a new hepatitis B vaccine for the protection of patients with renal insufficiency including pre-haemodialysis and haemodialysis patients. Expert Opin Biol Ther 2008;8: 235-47
87. Kensil CR, Kammer R. QS-21: a water-soluble triterpene glycoside adjuvant. Expert Opin Investig Drugs 1998;7:1475-82
88. Vandepapelière P, Horsmans Y, Moris P, et al. Vaccine adjuvant systems containing monophosphoryl lipid A and QS21 induce strong and persistent humoral and T cell responses against hepatitis B surface antigen in healthy adult volunteers. Vaccine 2008;26:1375-86
89. Beran J, Hobzova L, Wertzova V, et al. Safety and immunogenicity of an investigational adjuvanted hepatitis B vaccine (HB-AS02V) in healthy adults. Hum Vaccin 2010;6:578-84
90. Tielemans CL, Vlasak J, Kosa D, et al. Immunogenicity and safety of an investigational AS02(v)-adjuvanted hepatitis B vaccine in patients with renal insufficiency who failed to respond or to maintain antibody levels after prior vaccination: results of two open, randomized, comparative trials. Vaccine 2011;29:1159-66
91. Surquin M, Tielemans CL, Kulcsár I, et al. Rapid, enhanced, and persistent protection of patients with renal insufficiency by AS02 (V)-adjuvanted hepatitis B vaccine. Kidney Int 2010;77:247-55
92. Surquin M, Tielemans C, Nortier J, et al. Anti-HBs antibody persistence following primary vaccination with an investigational AS02(v)-adjuvanted hepatitis B vaccine in patients with renal insufficiency. Hum Vaccin 2011;7:913-18
93. Zhou Z, Chen WS, Yao JL. CpG oligodeoxynucleotide enhances humoral and cellular immune responses against HBsAg in mice. Article in Chinese Zhonghua Nei Ke Za Zhi 2003;42:640-2
94. Halperin SA, Ward B, Cooper C, et al. Comparison of safety and immunogenicity of two doses of investigational hepatitis B virus surface antigen co-administered with an immunostimulatory phosphorothioate oligodeoxyribonucleotide and three doses of a licensed hepatitis B vaccine in healthy adults 18-55 years of age. Vaccine 2012;30: 2556-63
95. Halperin SA, Ward BJ, Dionne M, et al. Immunogenicity of an investigational hepatitis B vaccine (hepatitis B surface antigen co-administered with an immunostimulatory phosphorothioate oligodeoxyribonucleotide) in nonresponders to licensed hepatitis B vaccine. Hum Vaccin Immunother 2013;9:1438-44
96. Sablan BP, Kim DJ, Barzaga NG, et al. Demonstration of safety and enhanced seroprotection against hepatitis B with investigational HBsAg-1018 ISS vaccine compared to a licensed hepatitis B vaccine. Vaccine 2012;30:2689-96
97. Heyward WL, Kyle M, Blumenau J, et al. Immunogenicity and safety of an investigational hepatitis B vaccine with a Toll-like receptor 9 agonist adjuvant (HBsAg-1018) compared to a licensed hepatitis B vaccine in healthy adults 40-70 years of age. Vaccine 2013;31:5300-5
98. Janssen RS, Mangoo-Karim R, Pergola PE, et al. Immunogenicity and safety of an investigational hepatitis B vaccine with a toll-like receptor 9 agonist adjuvant (HBsAg-1018) compared with a licensed hepatitis B vaccine in patients with chronic kidney disease. Vaccine 2013;31:5306-13
99. Heplisav Approval Status. Available from: www.drugs.com/history/heplisav.html [Last accessed 22 March 2014]
100. Saade F, Honda-Okubo Y, Trec S, et al. A novel hepatitis B vaccine containing AdvaxTM, a polysaccharide adjuvant derived from delta inulin, induces robust humoral and cellular immunity with minimal reactogenicity in preclinical testing. Vaccine 2013;31:1999-2007
101. Fakharzadeh S, Kalanaky S, Hafizi M, et al. The new nano-complex, Hep-c, improves the immunogenicity of the hepatitis B vaccine. Vaccine 2013;31:2591-7
102. Gray PM, Forrest G, Wisniewski T, et al. Evidence for cyclic diguanylate as a vaccine adjuvant with novel immunostimulatory activities. Cell Immunol 2012;278:113-19
103. Chen X, Zhang W, Gao W, et al. Hemokinin-1 as an adjuvant molecule enhancing humoral and memory responses to HBsAg DNA vaccination. Viral Immunol 2012;25:289-96
104. Health. Available from: www.nytimes.com/2011/04/07/health/07blumberg.html? pagewanted=all&-r=0 [Last accessed 28 March 2014]
105. ESRD. Available from: www.vision-fmc. com/files/download/ESRD/ESRD-Patients-in-2011.pdf [Last accessed 28 March 2014]